5-hydroxyindoleacetic Acid in the Diagnosis and Monitoring of PAH in Children after Congenital Heart Defect Surgical Correction

2025

Closed access Metadata (CSL-JSON)
DOI 10.52711/0974-360x.2025.00178
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

The clinical picture at the initial stage of pulmonary arterial hypertension is scanty and nonspecific, especially in young children, which makes it difficult to diagnose PAH and control the course of the disease. On average 2.5 years pass before the appearance of pronounced clinical symptoms and diagnosis, when there are already irreversible changes in the pulmonary artery vascular wall. We present the results of studying the concentration of 5-hydroxyindoleacetic acid (5-HIAA) in blood plasma in young children with PAH before and after surgical correction of congenital heart defects. The revealed increase of 5-HIAA in plasma in children in the early postoperative period can be used in the diagnosis of PAH and serve as a criterion for assessing the regression of pulmonary hypertension.